利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.014 秒)

    Compounds and therapeutic use thereof for protein kinase inhibition
    1.
    发明授权
    Compounds and therapeutic use thereof for protein kinase inhibition 有权
    用于蛋白激酶抑制的化合物及其治疗用途

    公开(公告)号：US09249154B2

    公开(公告)日：2016-02-02

    申请号：US13668197

    申请日：2012-11-02

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A61K31/5025 ,  C07D495/04

    CPC分类号： C07D495/04 ,  A61K31/5025

    摘要： Novel compound having the following formula: Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.

    摘要翻译： 具有下式的新型化合物：还公开了包含其的药物组合物，使用其的癌症治疗方法及其合成方法。 发现本发明的新化合物抑制蛋白激酶，特别是检查点激酶Chk1 / Chk2。

    2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof
    2.
    发明授权
    2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof 有权
    2,6-二氮杂的取代嘌呤衍生物，其制备和用途

    公开(公告)号：US08580763B2

    公开(公告)日：2013-11-12

    申请号：US12596669

    申请日：2008-04-17

    申请人： Zhanggui Wu ,  Weidong Ye ,  Jianyong Yuan ,  Gang Chen

    发明人： Zhanggui Wu ,  Weidong Ye ,  Jianyong Yuan ,  Gang Chen

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： C07D473/16 ,  C07H19/16 ,  C07H19/173 ,  C07H19/20

    摘要： The present invention provides 2,6-dinitrogen-containing substituted purine compounds of formula (A) or salts or solvates thereof or the solvates of salts thereof, as well as pharmaceutical compositions containing such compounds. The compounds of the present invention have the characteristics of lower toxicity, broad anticancer spectrum, higher anticancer activity, good stability and the like. The compounds are useful for the manufacture of an antitumor medicament. The present invention also provides a process for preparing these compounds.

    摘要翻译： 本发明提供式（A）的2,6-二氮的取代嘌呤化合物或其盐或溶剂合物或其盐的溶剂化物，以及含有这些化合物的药物组合物。 本发明化合物具有毒性低，抗癌谱广，抗癌活性高，稳定性好等特点。 该化合物可用于制造抗肿瘤药物。 本发明还提供了制备这些化合物的方法。

    NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION
    3.
    发明申请
    NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION 审中-公开
    用于蛋白激酶抑制的新型化合物及其治疗方法

    公开(公告)号：US20150072987A1

    公开(公告)日：2015-03-12

    申请号：US14333529

    申请日：2014-07-17

    申请人： Zhanggui WU

    发明人： Zhanggui WU

    IPC分类号： C07D495/04

    CPC分类号： C07D495/04

    摘要： Novel compound having the following formula: wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.

    摘要翻译： 具有下式的新化合物：其中Y是N，O或S.还公开了包含其的药物组合物，使用其的治疗癌症的方法及其合成方法。 发现本发明的新化合物抑制蛋白激酶，特别是检查点激酶Chk1 / Chk2。

    2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof
    4.
    发明申请
    2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof 有权
    2,6-Dinitrogen-Containing替代嘌呤衍生物，其制备和用途

    公开(公告)号：US20100144663A1

    公开(公告)日：2010-06-10

    申请号：US12596669

    申请日：2008-04-17

    申请人： Zhanggui Wu ,  Weidong Ye ,  Jianyong Yuan ,  Gang Chen

    发明人： Zhanggui Wu ,  Weidong Ye ,  Jianyong Yuan ,  Gang Chen

    IPC分类号： A61K31/52 ,  C07D473/16 ,  C07H19/16 ,  A61K31/7076 ,  A61P35/00

    CPC分类号： C07D473/16 ,  C07H19/16 ,  C07H19/173 ,  C07H19/20

    摘要： The present invention provides 2,6-dinitrogen-containing substituted purine compounds of formula (A) or salts or solvates thereof or the solvates of salts thereof, as well as pharmaceutical compositions containing such compounds. The compounds of the present invention have the characteristics of lower toxicity, broad anticancer spectrum, higher anticancer activity, good stability and the like. The compounds are useful for the manufacture of an antitumor medicament. The present invention also provides a process for preparing these compounds.

    摘要翻译： 本发明提供式（A）的2,6-二氮的取代嘌呤化合物或其盐或溶剂合物或其盐的溶剂化物，以及含有这些化合物的药物组合物。 本发明化合物具有毒性低，抗癌谱广，抗癌活性高，稳定性好等特点。 该化合物可用于制造抗肿瘤药物。 本发明还提供了制备这些化合物的方法。

    N2-quinoline or isoquinoline substituted purine derivatives
    5.
    发明授权
    N2-quinoline or isoquinoline substituted purine derivatives 失效
    N 2 - 喹啉或异喹啉取代的嘌呤衍生物

    公开(公告)号：US07399754B2

    公开(公告)日：2008-07-15

    申请号：US11452955

    申请日：2006-06-15

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/00 ,  C07H19/22

    CPC分类号： C07F9/65616 ,  C07D473/16 ,  C07H19/16

    摘要： Novel compound having the following formula: wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same.

    摘要翻译： 具有下式的新型化合物：其中W表示氢，任选取代的C 1-6烷基，任选取代的C 3-6环烷基或任选取代的C 1-6代表卤代烷基，Y代表氢或糖类，Q代表喹啉或异喹啉。 还公开了包含其的药物组合物，使用其的治疗癌症的方法及其合成方法。

    Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
    6.
    发明授权
    Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses 有权
    噻吩并哒嗪化合物，其制剂，药物组合物和用途

    公开(公告)号：US08962626B2

    公开(公告)日：2015-02-24

    申请号：US12811898

    申请日：2009-01-07

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A01N43/58 ,  A01N43/60 ,  A61K31/50 ,  A61K31/495 ,  C07D237/26 ,  C07D487/00 ,  C07D237/28 ,  C07D495/04

    CPC分类号： C07D495/04 ,  A61K31/5025

    摘要： The present invention relates to thienopyridazine compounds of formula (I), their pharmaceutically acceptable salts or hydrates, wherein R1 and R2 are independently H or C1-4 alkyl, R3 is a saturated or unsaturated 5- or 6-membered ring containing N, S or O, or its optical isomers, R4 is a halophenyl monosubstituted or disubstituted at any position. The present invention provides the preparation methods of these compounds, pharmaceutical compositions containing these compounds and the uses of these compounds, particularly in treating cancer.

    摘要翻译： 本发明涉及式（I）的噻吩并哒嗪化合物及其药学上可接受的盐或水合物，其中R 1和R 2独立地为H或C 1-4烷基，R 3为饱和或不饱和的含有N，S 或O或其旋光异构体，R4是在任何位置被卤代苯基单取代或二取代的。 本发明提供了这些化合物的制备方法，含有这些化合物的药物组合物以及这些化合物的用途，特别是用于治疗癌症。

    Compounds and therapeutic use thereof for protein kinase inhibition
    7.
    发明授权
    Compounds and therapeutic use thereof for protein kinase inhibition 有权
    用于蛋白激酶抑制的化合物及其治疗用途

    公开(公告)号：US08815863B2

    公开(公告)日：2014-08-26

    申请号：US13496494

    申请日：2010-09-17

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A01N43/58 ,  A61K31/50 ,  C07D237/26 ,  C07D495/02

    CPC分类号： C07D495/04

    摘要： Novel compound having the following formula: (I) wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.

    摘要翻译： 具有下式的新化合物：其中Y是N，O或S的（I）化合物。还公开了包含其的药物组合物，使用其的治疗癌症的方法及其合成方法。 发现本发明的新化合物抑制蛋白激酶，特别是检查点激酶Chk1 / Chk2。

    NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION
    8.
    发明申请
    NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION 有权
    用于蛋白激酶抑制的新型化合物及其治疗方法

    公开(公告)号：US20120232082A1

    公开(公告)日：2012-09-13

    申请号：US13496494

    申请日：2010-09-17

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A61K31/5025 ,  A61P35/00 ,  C07D495/04

    CPC分类号： C07D495/04

    摘要： Novel compound having the following formula: (I) wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.

    摘要翻译： 具有下式的新化合物：其中Y是N，O或S的（I）化合物。还公开了包含其的药物组合物，使用其的治疗癌症的方法及其合成方法。 发现本发明的新化合物抑制蛋白激酶，特别是检查点激酶Chk1 / Chk2。

    Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses
    9.
    发明申请
    Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses 有权
    噻吩并哒嗪化合物，其制剂，药物组合物和用途

    公开(公告)号：US20110009415A1

    公开(公告)日：2011-01-13

    申请号：US12811898

    申请日：2009-01-07

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： A61K31/5025 ,  C07D495/04 ,  A61P35/00 ,  A61P37/02 ,  A61P29/00 ,  A61P25/00 ,  A61P9/00 ,  A61P35/02

    CPC分类号： C07D495/04 ,  A61K31/5025

    摘要： The present invention relates to thienopyridazine compounds of formula (I), their pharmaceutically acceptable salts or hydrates, wherein R1 and R2 are independently H or C1-4 alkyl, R3 is a saturated or unsaturated 5- or 6-membered ring containing N, S or O, or its optical isomers, R4 is a halophenyl monosubstituted or disubstituted at any position. The present invention provides the preparation methods of these compounds, pharmaceutical compositions containing these compounds and the uses of these compounds, particularly in treating cancer.

    摘要翻译： 本发明涉及式（I）的噻吩并哒嗪化合物及其药学上可接受的盐或水合物，其中R 1和R 2独立地为H或C 1-4烷基，R 3为饱和或不饱和的含有N，S 或O或其旋光异构体，R4是在任何位置被卤代苯基单取代或二取代的。 本发明提供了这些化合物的制备方法，含有这些化合物的药物组合物以及这些化合物的用途，特别是用于治疗癌症。

    Compounds and therapeutic use thereof for protein kinase inhibition
    10.
    发明授权
    Compounds and therapeutic use thereof for protein kinase inhibition 有权
    用于蛋白激酶抑制的化合物及其治疗用途

    公开(公告)号：US09487539B2

    公开(公告)日：2016-11-08

    申请号：US14333529

    申请日：2014-07-17

    申请人： Zhanggui Wu

    发明人： Zhanggui Wu

    IPC分类号： C07D495/04

    CPC分类号： C07D495/04

    摘要： Novel compound having the following formula: wherein Y is N, O, or S. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, and methods for the synthesis of the same. The novel compounds of the present invention are found to inhibit protein kinases, especially Checkpoint kinase Chk1/Chk2.